CLINICAL TRIAL article
Front. Pharmacol.
Sec. Drug Metabolism and Transport
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1670582
Pharmacokinetics, safety and tolerability of ipatasertib in combination with palbociclib and fulvestrant in patients with advanced breast cancer in a Phase Ib study
Provisionally accepted
Kit Wun Kathy Cheung
Ksenia Arzumanova
Victor PoonAdam HarrisRyan JohnsonFrauke SchimmollerRucha Sane*- Genentech Inc., San Francisco, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Ipatasertib is a potent, highly selective, small molecule AKT inhibitor that has been evaluated in combination with palbociclib and fulvestrant for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Ipatasertib is a sensitive CYP3A4 substrate and is extensively metabolized to its major metabolite, M1 (G-037720). Ipatasertib is also a mild to moderate CYP3A inhibitor in vitro. Palbociclib is a weak time-dependent CYP3A inhibitor and a CYP3A substrate. Accordingly, drug-drug interaction (DDI) between ipatasertib and palbociclib is expected when the two drugs are co-administered. Methods: The study reported herein is a Phase Ib clinical trial that aimed to evaluate the safety and pharmacokinetics (PK) of 300 mg ipatasertib in combination with palbociclib and fulvestrant (NCT04060862). The ipatasertib and M1 PK at steady state as a single agent were compared to that in combination with palbociclib and fulvestrant to evaluate the magnitude of DDI between ipatasertib and palbociclib. Results: The PK analysis showed that the area under the concentration-time curve from time 0 to 24 hours at steady state (AUC0-24,ss) and the maximum observed plasma concentration at steady state (Cmax,ss) of ipatasertib increased by 68% and 49%, respectively, when ipatasertib was coadministered with palbociclib and fulvestrant compared to administration of ipatasertib alone. A similar trend was observed for M1 with AUC0-24,ss and Cmax,ss increased by 20% and 14%, respectively, when ipatasertib was coadministered with palbociclib and fulvestrant compared to administration of ipatasertib alone. Palbociclib plasma trough concentrations at steady state were generally comparable with historical data. Conclusion: This study indicated a DDI between ipatasertib and palbociclib, leading to increased ipatasertib exposure. The combination regimen of ipatasertib 300 mg with palbociclib and fulvestrant had a notable and manageable safety profile, that is gnerally consistent with the known risks of each individual study drugs in patients with HR+ HER2- breast cancer.
Keywords: ipatasertib, breast cancer, clinical study, drug-drug interactions, cyp3a
Received: 21 Jul 2025; Accepted: 26 Aug 2025.
Copyright: © 2025 Cheung, Arzumanova, Poon, Harris, Johnson, Schimmoller and Sane. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Rucha Sane, Genentech Inc., San Francisco, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.